Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development.
about
Diffusion-weighted magnetic resonance imaging in cancer: Reported apparent diffusion coefficients, in-vitro and in-vivo reproducibilityPreclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomographyESR statement on the stepwise development of imaging biomarkers.Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastographyApparent diffusion coefficient is highly reproducible on preclinical imaging systems: Evidence from a seven-center multivendor study.Diffusion-weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy.Response Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases.Improving CT-guided transthoracic biopsy of mediastinal lesions by diffusion-weighted magnetic resonance imaging.Early detection of Lewis lung carcinoma tumor control by irradiation using diffusion-weighted and dynamic contrast-enhanced MRI.Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastomaApparent diffusion coefficient values of diffusion-weighted imaging for distinguishing focal pulmonary lesions and characterizing the subtype of lung cancer: a meta-analysis.Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.The Accuracy of ADC Measurements in Liver Is Improved by a Tailored and Computationally Efficient Local-Rigid Registration AlgorithmPredicting outcomes in radiation oncology--multifactorial decision support systemsA Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment.Development of a diffusion-weighted MRI protocol for multicentre abdominal imaging and evaluation of the effects of fasting on measurement of apparent diffusion coefficients (ADCs) in healthy liverEvaluation of connectivity map-discovered celastrol as a radiosensitizing agent in a murine lung carcinoma model: Feasibility study of diffusion-weighted magnetic resonance imaging.Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.Functional MRI and CT biomarkers in oncology.The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.A data-driven statistical model that estimates measurement uncertainty improves interpretation of ADC reproducibility: a multi-site study of liver metastases.Intravoxel incoherent motion model-based liver lesion characterisation from three b-value diffusion-weighted MRI.Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.Associations between apparent diffusion coefficient (ADC) and KI 67 in different tumors: a meta-analysis. Part 1: ADCmean.UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer.Diffusion-weighted magnetic resonance imaging for assessment of lung lesions: repeatability of the apparent diffusion coefficient measurement.Associations between apparent diffusion coefficient (ADC) and KI 67 in different tumors: a meta-analysis. Part 2: ADCmin.
P2860
Q26770403-71DA9F16-9505-40A7-A5E2-0A00243C3C54Q28540769-4CDAACF8-E1FC-46D1-BD26-80370FCBFB59Q30456007-702B0138-F2BF-4827-B23E-F3E9F5862916Q30764503-9C6A2CE7-BB2E-482E-8557-F2812125EAFBQ30959022-7DD1C8E2-EDE6-4969-A59A-F516E9BA0C81Q31123171-2A65CA10-46F4-4142-A4FA-DA56BAA2AA80Q33875886-F7C1FF49-2A69-4E67-9716-5BC041208739Q34628155-16E7ACFB-E3F9-421B-B1A9-91FCAB58876AQ34712745-AEF14FF5-C36B-485F-99CB-F1E1471B1578Q34983575-85E05D71-0067-449D-85E6-2230199AA1FFQ35640148-E399263A-D47E-46E1-BDF4-FB37B98F7946Q35677936-B0467479-2F61-4CF2-9F73-18E151F00189Q35708156-896FD886-546C-4632-A6BD-F4679A2EA2B4Q36014711-C00B9C71-24EA-483D-8996-6F49EC0FC9FFQ36021562-F90C55AF-9221-4259-AE95-458585C8F5D5Q36235539-CB39D007-1167-46D5-8BDB-ED06B3CA96E6Q36381094-BEE82922-01F4-4EA6-A8B9-7BF846256CE2Q37182194-AA9C04DA-5594-4567-AECE-A69AF29DF9BCQ38314429-EB491CC8-1297-4A9A-B2C8-E771019D443AQ38907580-590196F9-70EC-4ADF-97E6-FBF0C3093114Q42620668-C1CD3FDB-05AB-43EF-BA9B-90569AFB6562Q45823751-A717083B-C348-498E-B7F4-157ABC5BBB27Q45933675-39822869-C5EF-4F4B-8FC5-37DCF4EBD299Q47159882-4F2B4115-58F5-4E03-BB8A-DFBB03AE62BEQ47404572-CC941C4D-7901-4A59-9276-05A61CD22035Q53087697-F9ED14AC-9F28-4202-8FAA-AF6431ADA773Q55317843-0458934C-84B8-4EFE-A3BC-157003DDA5D0
P2860
Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Apparent diffusion coefficient ...... in oncology drug development.
@ast
Apparent diffusion coefficient ...... in oncology drug development.
@en
Apparent diffusion coefficient ...... in oncology drug development.
@nl
type
label
Apparent diffusion coefficient ...... in oncology drug development.
@ast
Apparent diffusion coefficient ...... in oncology drug development.
@en
Apparent diffusion coefficient ...... in oncology drug development.
@nl
prefLabel
Apparent diffusion coefficient ...... in oncology drug development.
@ast
Apparent diffusion coefficient ...... in oncology drug development.
@en
Apparent diffusion coefficient ...... in oncology drug development.
@nl
P2093
P1476
Apparent diffusion coefficient ...... r in oncology drug development
@en
P2093
Nandita DeSouza
Ralph Sinkus
Valérie Vilgrain
P304
P356
10.1016/J.EJCA.2011.11.034
P577
2012-01-05T00:00:00Z